MetLife Investment Management LLC Has $7.14 Million Holdings in Insmed Incorporated (NASDAQ:INSM)

MetLife Investment Management LLC boosted its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 15.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 103,429 shares of the biopharmaceutical company's stock after purchasing an additional 13,807 shares during the period. MetLife Investment Management LLC owned 0.06% of Insmed worth $7,141,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Insmed in the 4th quarter valued at approximately $126,606,000. Vanguard Group Inc. grew its holdings in shares of Insmed by 6.3% during the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after acquiring an additional 1,075,796 shares in the last quarter. Capital International Investors increased its stake in shares of Insmed by 9.1% in the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock worth $491,357,000 after acquiring an additional 593,206 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Insmed by 38.0% during the fourth quarter. Marshall Wace LLP now owns 1,064,215 shares of the biopharmaceutical company's stock worth $73,473,000 after acquiring an additional 293,004 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Insmed by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock valued at $282,243,000 after purchasing an additional 273,759 shares during the last quarter.

Insider Activity at Insmed

In other news, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $77.94, for a total transaction of $1,461,375.00. Following the transaction, the chief executive officer now directly owns 379,534 shares of the company's stock, valued at $29,580,879.96. This trade represents a 4.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Sara Bonstein sold 18,322 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the completion of the sale, the chief financial officer now owns 118,863 shares of the company's stock, valued at approximately $9,545,887.53. This represents a 13.36 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 471,797 shares of company stock worth $37,621,239. 3.00% of the stock is currently owned by company insiders.

Insmed Trading Down 0.3 %

Shares of NASDAQ:INSM traded down $0.21 during midday trading on Monday, hitting $69.48. The company had a trading volume of 1,078,526 shares, compared to its average volume of 2,301,941. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91. The firm has a fifty day simple moving average of $74.38 and a 200 day simple moving average of $73.57. The stock has a market cap of $12.63 billion, a price-to-earnings ratio of -12.43 and a beta of 1.07.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Wall Street Analyst Weigh In

INSM has been the subject of a number of recent research reports. JPMorgan Chase & Co. raised their price target on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. Guggenheim reaffirmed a "buy" rating and set a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. UBS Group boosted their target price on shares of Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Finally, Stifel Nicolaus decreased their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Insmed has a consensus rating of "Moderate Buy" and an average price target of $94.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.